Santen Pharmaceutical has signed a licensing agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein designed to treat retinal diseases. The agreement, facilitated ...
YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced ...
The RC28 Travel Awards Fund assists students and members in special needs by subsidising their travel to RC28 conferences, in order to present their work. The travel awards are also given in ...
Team associated rc28 parts online, TEAM ASSOCIATED AE QUALIFIER SERIES SC28 1 28 SC FOX FACTORY TEAM online ...
China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250 million Chinese yuan ($34.8 million) upfront. The drug in question, dubbed ...
YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: SH/09995, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement ...
RemeGen Co., Ltd., a leading Chinese biopharmaceutical company, announced that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. (Santen China), a wholly-owned subsidiary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results